The first article, by Dr Dominique Morisano, Dr Ingrid Bacher, Dr Janet Audrain-McGovern, and Dr Tony George, 8 reviews biobehavioural, psychological, and social and (or) environmental determinants of tobacco comorbidity in MHA populations. Converging lines of evidence in the past 20 years indicate that having an MHA diagnosis appears to be a vulnerability factor for the initiation and maintenance of tobacco use and tobacco dependence (TD). Moreover, there is some limited evidence in some mental health disorders (for example, schizophrenia and major depressive disorder [MDD] ) that nicotine, the major component of tobacco that leads to drug reinforcement, may actually produce beneficial effects, such as remediation of cognitive deficits in people with schizophrenia [9] [10] [11] and improvement of depressive symptoms in MDD. [12] [13] [14] There are also other explanations for the high rates of TD in these populations, including vulnerability to addiction and enhanced nicotine withdrawal. Clearly more research is needed on this topic. Accordingly, increased knowledge about the role of nicotinic receptors and pathways in MHA disorders has the potential to be translated into novel and more effective treatments, both for the MHA disorders and for comorbid tobacco addiction in these patients, who bear a disproportionate burden of the economic, social, and health care costs associated with tobacco addiction. 15 The second article, by Dr Brian Hitsman, Ms Taryn D Moss, Dr Ivan D Montoya, and Dr George, 16 describes an evidencebased approach to, and available clinical research data supporting the use of, pharmacological and behavioural interventions for TD treatment in MHA populations. Clearly such treatment is best done in an integrated setting where both treatment for the MHA disorder and the comorbid tobacco addiction are done by the same clinicians in the same facility. 17, 18 In addition, these populations appear to benefit from integrated treatment that includes psychosocial and pharmacological treatments. However, most studies in treatment-seeking MHA smokers have been of a small sample size, and performed at a single site, typically in an academic tertiary health care setting. This has led to limited progress in this field insofar as developing treatments for widespread dissemination and implementation in community settings, where most MHA smokers are managed. A growing number of studies have confirmed that while cessation rates are low, tobacco reduction and cessation in MHA smokers is possible, and in fact some of the more recent studies in smokers with schizophrenia, 19, 20 which have used optimized treatment strategies, including nicotine replacement therapies, sustained-release bupropion, and cognitive-behavioural and motivational therapies, have produced short-and long-term (6 month) quit rates that approach those in noncomorbid smokers. 21 Further, while TD is considered a chronic illness, studies that have examined extended treatments in MHA populations are rare. However, one recent study 17 in smokers with a history of MDD achieved very high long-term cessation rates (about 50%) with extended treatment of up to a 1-year duration. Clearly we need to consider maintenance treatments for MHA and other smokers who initially respond to treatment, and provide ongoing treatment support for those who do not initially quit, as success is often seen in smokers who initially reduce but do not quit, as an eventual transition toward abstinence, which may in fact be a more realistic approach to tobacco treatment in these smokers. 22 One major challenge in implementing tobacco treatment relates to policies that govern the environment within which we treat these patients. Most MHA facilities have attempted to restrict or enforce an outright ban on the possession and use of tobacco products in their facilities. However, this has proven to be difficult for numerous reasons. Tobacco use is typically part of the culture of MHA settings, and there is often resistance to changing this culture by patients, their families, and staff and physicians, who believe that this is an important right for patients, 23 as it gives them social and psychiatric benefits (facilitates socialization, and reduces boredom and medication side effects 1 ), and serves as part of the token economy that is often characteristic in chronic institutional settings. This clearly conflicts with health promotion efforts in the institutional setting. The recent exemptions to tobacco bans in public institutions that have been granted to extended care facilities (including nursing homes, psychiatric hospitals, and drug treatment facilities) send a mixed message to patients, families, and staff who work in these settings, and may in fact perpetuate a double stigma as our patients already suffer considerable stigma in living with their mental illness or addictions. The corollary is that when we allow patients to smoke in facilities where they are treated (and often reside in while receiving long-term treatment), it suggests that institutions and governments do not fully recognize the risks of long-term tobacco addiction in MHA patients. There is considerable evidence that implementation of tobacco bans in these settings is practical and achievable, and with proper behavioural and pharmacological supports to manage tobacco withdrawal and cravings, combined with linkage to outpatient tobacco treatment services, the implementation of tobacco-free MHA treatment settings is possible and necessary. 24 Organizational change efforts are needed, including effective leadership and clear goals for the patients, staff, and environment. Tactics to achieve the goals can be spelled out in a strategic plan that includes improving treatment planning, services for lower and higher motivated patients, training for staff and administrators, recovery resources for staff and administrators who are smokers themselves, and clear environmental policies and changes to support a smoke-free environment. There is guidance in the literature about how institutional tobacco policy changes can be achieved. 24, 25 Tobacco comorbidity is clearly an important problem for psychiatry, and it is hoped that this series will encourage psychiatrists and other mental health professionals to become skilled in identifying tobacco use and initiating treatment, given that this is seldom done by these providers. 26, 27 The safety of tobacco interventions in this population has been documented, 20, 28, 29 and given that TD appears to be a treatable chronic disorder to which most of our MHA patients will eventually succumb, continuing research into the determinants of tobacco and MHA comorbidity and treatment approaches should be a priority for governments and health research funding agencies in the future.
